- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01529671
A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee
An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-05089771 In Healthy Subjects And In Subjects With Osteoarthritis Of The Knee
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, B-1070
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subjects or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive.
- elderly cohort : healthy male and/or female subjects of 65 and 74 years,
- cohort 3: subjects with osteoarthritis of the knee: Male or female subjects not of child bearing potential between the ages of 18 and 75 years inclusive at the time of entering the study.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
- Treatment with an investigational drug within 60 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
- 12-lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec at Screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
- Use of prescription or non-prescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
- Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
for cohort 3: Evidence of relapse or recurrence of clinically significant endocrine, metabolic, pulmonary, hepatic, osteo-mio-artricular, gastrointestinal, cardiovascular, renal, , psychiatric or neurological disease, or neurological disease less than 28 days prior to screening.
Symptomatic OA of the hip ipsilateral to index knee which the patient considers more painful than the knee. History of diseases other than OA that may involve the index knee in the last 12 months prior to screening, including but not limited to: inflammatory joint diseases (i.e rehumatoid arthritis and gout), calcium crystal diseases, bursitis, tendinitis, tumors and cysts, ligament injuries, bone fractures, post-infective pathologies; widespread chronic pain conditions (ie, fibromyalgia) and neuropathic disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Experimental intervention: PF-05089771 or placebo
Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
|
PF-05089771 will be dosed as a suspension twice daily (BID)
PF-05089771 will be dosed as a suspension BID
|
Experimental: Cohort 2: Experimental intervention: PF-05089771 or placebo
Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
|
PF-05089771 will be dosed as a suspension twice daily (BID)
PF-05089771 will be dosed as a suspension BID
|
Experimental: Cohort 3: Experimental intervention: PF-05089771 or placebo
Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
|
PF-05089771 will be dosed as a suspension twice daily (BID)
PF-05089771 will be dosed as a suspension BID
|
Experimental: Cohort 4: Experimental intervention: PF-05089771 or placebo
Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
|
PF-05089771 will be dosed as a suspension twice daily (BID)
PF-05089771 will be dosed as a suspension BID
|
Experimental: Cohort 5: Experimental intervention: PF-05089771 or placebo
Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
|
PF-05089771 will be dosed as a suspension twice daily (BID)
PF-05089771 will be dosed as a suspension BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events as a measure of safety and tolerability of PF-05089771
Time Frame: Days 1-16
|
Days 1-16
|
Maximum concentration (Cmax) for PF-05089771 in plasma (measured in ng/mL)
Time Frame: Days 1, 4 and 14
|
Days 1, 4 and 14
|
Tmax = Time of maximum concentration of PF-05089771 in plasma (hr)
Time Frame: Days 1, 6 and 14
|
Days 1, 6 and 14
|
AUCtau= Area under the curve from the time of dosing to the next dose (ng.hr/mL)
Time Frame: Days 1, 6 and 14
|
Days 1, 6 and 14
|
Elimination half life (hr) = rate of elimination of PF-05089771 after the final dose
Time Frame: day 14 PK samples collected only for 48 hours
|
day 14 PK samples collected only for 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCinf = Area under the curve from the time of dosing extrapolated to infinity (ng.hr/mL)
Time Frame: Days 14, over 48 hours of PK samples collection
|
Days 14, over 48 hours of PK samples collection
|
Daily pain score throughout the treatment period using an 11-point Numeric Rating Scale (NRS).
Time Frame: Days 14, every day over 24 hours
|
Days 14, every day over 24 hours
|
Daily time to ascend and descend stairs.
Time Frame: Days 14, every day over 24 hours
|
Days 14, every day over 24 hours
|
Daily pain following stair climbing and descending
Time Frame: Days 14, every day over 24 hours
|
Days 14, every day over 24 hours
|
Daily time for self paced walk
Time Frame: Days 14, every day over 24 hours
|
Days 14, every day over 24 hours
|
Daily pain following self paced walk.
Time Frame: Days 14, every day over 24 hours
|
Days 14, every day over 24 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- B3291011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on PF-05089771
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompletedInherited ErythromelalgiaUnited States
-
PfizerCompletedDiabetic Neuropathy, PainfulUnited States
-
Metropolitan Eye Research & Surgery InstituteStanford University; Mallinckrodt; Ocular Imaging Research and Reading Center; Foresight...RecruitingScleritisUnited States